Unique ID issued by UMIN | UMIN000051795 |
---|---|
Receipt number | R000059045 |
Scientific Title | Effect of Test Food Consumption on Visual Function and Its Safety. |
Date of disclosure of the study information | 2023/08/02 |
Last modified on | 2024/02/22 15:13:51 |
Effect of Test Food Consumption on Visual Function and Its Safety.
Effect of Test Food Consumption on Visual Function and Its Safety.
Effect of Test Food Consumption on Visual Function and Its Safety.
Effect of Test Food Consumption on Visual Function and Its Safety.
Japan |
No
Not applicable | Adult |
Others
NO
This study aims to examine effect of test food consumption on visual function and its safety.
Safety,Efficacy
*Visual function-related tests
・Fundus Blood Flow (optic nerve head and choroid ). (1)
・Dynamic visual acuity test. (1)
・Near vision. (2)
・Depth perception. (2)
・Dark adaptation. (2)
(1):Screening, Observation Period I, Observation Period II.
(2):Observation Period I, Observation Period II.
* Secondary indexes
1) Visual Analogue Scale. (1)
* Safety
1) Blood pressure, pulsation. (1)
2) Weight, body fat percentage, BMI. (1)
3) Doctor's questions / Adverse events. (1)
4) Subject's diary. (2)
* Other indexes
1) Baseline characteristics. (3)
2) Height measurement. (3)
3) Ophthalmic examination. (3)
・visual acuity.
・refraction test.
・dominant eye judgement.
・intraocular pressure measurement.
・fundus examination.
・slit-lamp microscopy.
(1):Screening, Observation Period I, Observation Period II.
(2):From Observation Period I to the last day of the test
(3):Screening
Interventional
Cross-over
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
[1] Oral ingestion of a test food (1 tablet in a day; 2 weeks).
[2] Observation.
[3] Washout (2weeks).
[4] Oral ingestion of a placebo food (1 tablet in a day; 2 weeks).
[5] Observation.
[1] Oral ingestion of a placebo food (1 tablet in a day; 2 weeks).
[2] Observation.
[3] Washout (2weeks).
[4] Oral ingestion of a test food (1 tablet in a day; 2 weeks).
[5] Observation.
20 | years-old | <= |
65 | years-old | > |
Male and Female
1) Japanese males and females aged 20-64 years.
2) Individuals who are healthy and are not received treatment of disease.
3) Individuals who have binocular vision of 0.7 or better with naked eye or corrected vision, and who do not wear contact lenses.
4) Individuals whose written informed consent has been obtained.
5) Individuals who can come to the designated venue for this study and be inspected.
6) Individuals judged appropriate for the study by the principal.
1) Individuals using medical products.
2) Individuals with a history or present history of mental illness, sleep disorder, hypertension, diabetes, dyslipidemia, eye disease, or other serious illness.
3) Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease.
4) Individuals who are a patient or have a history of or endocrine disease.
5) Individuals who used a drug to treat a disease in the past 1 month.
6) Individuals who use intraocular lens.
7) Individuals whose BMI is over 30 kg/m2.
8) Individuals with drug and food allergies.
9) Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements which claim to improve eye-related functions or contain bilberry or active ingredients that are expected to have an effect on the eyes in the past 3 months or will ingest those foods during the test period.
10) Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60g/day).
11) Individuals with possible changes of life style during the test period.
12) Individuals who engage in a night work.
13) Individuals who are or are possibly pregnant, or are lactating.
14) Individuals who participated in other clinical studies in the past 3 months.
15) Individuals who are or whose family is engaged in healthy or functional foods.
16) Individuals who are unable to follow instructions from the study supervisor or who judged inappropriate for the study by the principal.
30
1st name | Atsushi |
Middle name | |
Last name | Nakajima |
Ueno-Asagao Clinic
Head
110-0015
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
+81-3-6240-1162
info@ueno-asagao.clinic
1st name | Ryoma |
Middle name | |
Last name | Shimizu |
TES Holdings Co., Ltd.
Administrative Department of Clinical Trials
110-0015
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
+81-3-6801-8480
r.shimizu@tes-h.co.jp
TES Holdings Co., Ltd.
Omnica Co.,Ltd
Profit organization
Ueno-Asagao Clinic Ethical Review Committee
6F Kairaku Building 2-7-5 Higashiueno Taito-ku Tokyo 110-0015, JAPAN
+81-3-6240-1162
jimukyoku@tes-h.co.jp
NO
2023 | Year | 08 | Month | 02 | Day |
Unpublished
Completed
2023 | Year | 07 | Month | 26 | Day |
2023 | Year | 07 | Month | 27 | Day |
2023 | Year | 08 | Month | 16 | Day |
2023 | Year | 10 | Month | 03 | Day |
2023 | Year | 08 | Month | 02 | Day |
2024 | Year | 02 | Month | 22 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059045
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |